Rankings / Essentials — Supplements

Omega-3 (EPA/DHA)

Essentials · Supplement

Also known as: Fish oil ·EPA ·DHA

Tier B+

Reviewed by Read Off Label · Last reviewed · How we grade

omega-3anti-inflammatoryaf-dose-responseapoe4otcspm-precursor
7.4 / 10
Tier B+
Ev 8 Bn 6.5 Sf 7

Bottom line

Read Off Label grades Omega-3 (EPA/DHA) as B+ (7.4/10) based on strong evidence, med-high benefit magnitude, and a low-med-risk safety profile.

Per 2024-2025 evidence the signal shape is now clearer.

Studied, labeled, or reported-use context: 500 mg-1 g combined EPA+DHA/day for general use; up to 4 g EPA-only for HTG (Rx); Omega-3 Index >8% is… — OTC; not individualized guidance.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Reverses on stopping

Membrane incorporation reverses over months after stopping. Effects on bleeding time normalise within weeks.

Can you tell if it worked?

Readable — 3–4 months for the index to plateau

An Omega-3 Index blood test is the rare case of a directly measurable compliance-and-exposure endpoint. Triglycerides on a standard panel if that is the goal.

What would fool you Fish intake between tests changes the result. Triglycerides are highly sensitive to recent alcohol and carbohydrate intake, so fast properly and keep the fortnight before each test comparable.

What the evidence says

Per 2024-2025 evidence the signal shape is now clearer. (1) AF dose-response: the AF risk is real and dose-dependent at supplemental levels, but observational dietary-intake data show the OPPOSITE — higher plasma DHA+EPA associates with 6-10% LOWER AF risk in UK Biobank. Mechanism: low-level vagal stimulation reduces AF; high-level increases it. Dietary intake and supplemental dosing show different AF associations; prescription-level doses are studied and approved for specific indications and carry a higher AF signal. (2) EPA-only > combined: REDUCE-IT (4 g icosapent) positive; STRENGTH (mixed EPA+DHA carboxylic acid) neutral; RESPECT-EPA 2024 Japan (1.8 g icosapent, n=2460) just missed primary p=0.055 but secondary coronary HR 0.73 — supports the EPA-specific signal at lower dose AND independent of the disputed mineral-oil placebo issue. (3) Cognition: PreventE4 (Oct 2024 CTAD, n=365, 2 g DHA/day × 2 yr) missed primary WMH endpoint overall but APOE4 carriers had significantly less annual decline in white-matter integrity — emerging personalization angle. (4) Supplement quality: 2023 multi-year analysis of 72 supplements — 68% of flavored and 13% of unflavored exceeded GOED TOTOX ≤26 limit; children's products worst. Third-party oxidation testing uses TOTOX thresholds (<10 as a stringent benchmark; <26 as the GOED limit); fresh oil is typically almost odorless. Confirmed 2026: Shayan MA (25 RCTs, n=25,578) — combined EPA+DHA in secondary prevention or perioperative: no MACE benefit (p=0.40), no AF/POAF benefit (p=0.19), consistent with STRENGTH and the EPA-only-distinction framing above. Yanagisawa 2026 (real-world Japanese cohort, n=9,178): higher plasma EPA, DHA, EPA+DHA each independently and inversely associated with prevalent AF after adjustment — strengthens the "diet first, supplements modestly" angle and the biphasic dose-response narrative.

Mechanism

Incorporates into cell membranes (RBC; cardiomyocyte; neuronal); lowers triglycerides; substrate for anti-inflammatory eicosanoids and specialized pro-resolving mediators (resolvins/protectins/maresins); membrane fluidity; modulates vagal tone (dose-dependent and biphasic — explains AF dose-response)

Studied, labeled, or reported dose & route

500 mg-1 g combined EPA+DHA/day for general use; up to 4 g EPA-only for HTG (Rx); Omega-3 Index >8% is an observational target associated with lower CV mortality

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Omega-3 (EPA/DHA)'s effects?
Read Off Label rates the evidence for Omega-3 (EPA/DHA) as Strong and the benefit magnitude as med-high, producing an overall grade of B+ (7.4/10). Per 2024-2025 evidence the signal shape is now clearer.
What safety findings are reported for Omega-3 (EPA/DHA)?
Omega-3 (EPA/DHA) has a low-med risk profile in the database. Low-Med (dose- and risk-stratified AFib signal: the 2026 updated MA of 35 trials, n=114,592, found a significant AF increase only with high-dose EPA+DHA >1500 mg/d in patients at high cardiovascular risk - OR 1.43, 95% CI 1.14-1.79, absolute risk difference 0.8%; not statistically significant for low-dose in high-risk patients (OR 1.07), high-dose in low-risk (OR 1.03), or low-dose in low-risk (OR 1.06); bleeding risk with anticoagulants at high doses; rancid product GI upset) Legal status: OTC (Rx forms for severe HTG).
What doses or routes are reported for Omega-3 (EPA/DHA)?
500 mg-1 g combined EPA+DHA/day for general use; up to 4 g EPA-only for HTG (Rx); Omega-3 Index >8% is an observational target associated with lower CV mortality This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Omega-3 (EPA/DHA) work?
Incorporates into cell membranes (RBC; cardiomyocyte; neuronal); lowers triglycerides; substrate for anti-inflammatory eicosanoids and specialized pro-resolving mediators (resolvins/protectins/maresins); membrane fluidity; modulates vagal tone (dose-dependent and biphasic — explains AF dose-response)

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.